[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Correction
March 3, 2004

Efalizumab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial

JAMA. 2004;291(9):1070. doi:10.1001/jama.291.9.1070

Incorrect Table: In the Original Contribution entitled "Efaluzimab for Patients With Moderate to Severe Plaque Psoriasis: A Randomized Controlled Trial" published in the December 17, 2003, issue of THE JOURNAL (2003;290:3073-3080), Table 3 contained erroneous numbers for mean (SD) and median (IQR) placebo group improvement; additionally, erroneous PASI improvement percentage headings were shown. The correct table is shown below.

Table 3. DLQI Improvement Stratified by PASI Response at Week 12
Table 3. DLQI Improvement Stratified by PASI Response at Week 12
Image description not available.
×